Tecentriq SC: Revolutionizing Lung Cancer Treatment in India

Roche launched its atezolizumab injection, Tecentriq SC, in India to treat lung cancer. This subcutaneous injection reduces hospital time, administering in seven minutes versus hours for traditional IV infusions. Tecentriq SC aims to improve patient access and streamline cancer care across healthcare systems.

In a significant development for lung cancer treatment, Swiss pharmaceutical giant Roche announced the introduction of the atezolizumab injection, Tecentriq SC, in India. The cutting-edge subcutaneous treatment aims to minimize hospital visits by reducing administration time to just seven minutes, compared to hours needed for traditional intravenous infusions.

According to Roche Pharma India, Tecentriq SC's swift administration promises not only to relieve pressure on hospital resources but also enhance patient accessibility to treatment. With an annual diagnosis of 80,000 lung cancer cases, the innovation could substantially increase patient reach and improve the treatment experience.

By decentralizing care from tertiary centers to more accessible daycare settings, Roche aims to improve healthcare efficiency. The availability of Tecentriq SC in 85 countries, already benefiting over 10,000 patients, underscores its potential to optimize cancer treatment infrastructure, making advanced care more convenient and patient-focused.